生物
2019年冠状病毒病(COVID-19)
2019-20冠状病毒爆发
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
路径(计算)
倍他科诺病毒
大流行
冠状病毒感染
病毒学
进化生物学
计算生物学
爆发
传染病(医学专业)
疾病
内科学
程序设计语言
医学
计算机科学
作者
Michael J. Peluso,Steven G. Deeks
出处
期刊:Cell
[Elsevier]
日期:2024-09-01
被引量:9
标识
DOI:10.1016/j.cell.2024.07.054
摘要
Long COVID, a type of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PASC) defined by medically unexplained symptoms following infection with SARS-CoV-2, is a newly recognized infection-associated chronic condition that causes disability in some people. Substantial progress has been made in defining its epidemiology, biology, and pathophysiology. However, there is no cure for the tens of millions of people believed to be experiencing long COVID, and industry engagement in developing therapeutics has been limited. Here, we review the current state of knowledge regarding the biology and pathophysiology of long COVID, focusing on how the proposed mechanisms explain the physiology of the syndrome and how they provide a rationale for the implementation of a broad experimental medicine and clinical trials agenda. Progress toward preventing and curing long COVID and other infection-associated chronic conditions will require deep and sustained investment by funders and industry.
科研通智能强力驱动
Strongly Powered by AbleSci AI